InMode

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.

wall_street_photo_by_marek_masik_on_shutterstock copy

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Commodities

Global

Econ #s

Economics

Markets

Tech

$BTC

AMCR

AMGN

ARMK

ATKR

AXTA

AZPN

BALL

BERY

CNHI

SPDR Dow Jones Industrial Average ETF Trust

ENPH

FICO

FOXA

GOOG

GOOGL

HLNE

HUBB

ILMN

INGR

INMD

JKHY

LANC

MDLZ

MLAB

MPLX

MSGS

OCSL

PINC

PLTR

PYPL

RACE

REGN

SLAB

SPOT

U.S. stocks advanced midday Tuesday, demonstrating resilience despite escalating geopolitical tensions and trade uncertainties between the world’s two largest economies.

US Stocks Rise Despite China&#39;s Trade Fears, Palantir Defies Gravity, Gold Rallies Further: What&#39;s Driving Markets Tuesday?

Article Image (3) (1)

Opinion

Under the Radar: From Overlooked to Overperforming - Global Markets Await

GileadSciences.Shutterstock

News

Price Target

Initiation

Pre-Market Outlook

Analyst Ratings

Trading Ideas

ALMS

FWRG

GILD

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

InMode Ltd

Press Releases

InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

Earnings

InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)

InMode to Present at Upcoming Investor Conferences

InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025,  Expects Q4 Revenue Between $97.0M-$97.5M

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback

InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced

InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program

Comments

InMode

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga